ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 221 Thousand EUR | 50.34% |
| 2022 | 147 Thousand EUR | -16.95% |
| 2021 | 177 Thousand EUR | 365.79% |
| 2020 | 38 Thousand EUR | 0.0% |
| 2019 | - EUR | 100.0% |
| 2018 | -1.29 Million EUR | 10.91% |
| 2017 | -1.45 Million EUR | 61.3% |
| 2016 | -3.76 Million EUR | -65.66% |
| 2015 | -2.27 Million EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 201 Thousand EUR | 0.0% |
| 2023 Q1 | 159 Thousand EUR | 8.16% |
| 2023 Q3 | 221 Thousand EUR | 38.99% |
| 2023 Q4 | 221 Thousand EUR | 0.0% |
| 2023 FY | 221 Thousand EUR | 50.34% |
| 2023 Q2 | 159 Thousand EUR | 0.0% |
| 2022 Q2 | 137 Thousand EUR | 0.0% |
| 2022 Q3 | 147 Thousand EUR | 7.3% |
| 2022 FY | 147 Thousand EUR | -16.95% |
| 2022 Q1 | 137 Thousand EUR | -22.6% |
| 2022 Q4 | 147 Thousand EUR | 0.0% |
| 2021 Q4 | 177 Thousand EUR | 0.0% |
| 2021 FY | 177 Thousand EUR | 365.79% |
| 2021 Q3 | 177 Thousand EUR | 785.0% |
| 2021 Q2 | 20 Thousand EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2020 Q1 | - EUR | 100.0% |
| 2020 Q3 | - EUR | 100.0% |
| 2020 Q4 | 38 Thousand EUR | 0.0% |
| 2020 Q2 | -197 Thousand EUR | 0.0% |
| 2020 FY | 38 Thousand EUR | 0.0% |
| 2019 Q4 | -1.77 Million EUR | 0.0% |
| 2019 Q3 | - EUR | 100.0% |
| 2019 Q2 | -1.59 Million EUR | 0.0% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | - EUR | 100.0% |
| 2018 FY | -1.29 Million EUR | 10.91% |
| 2018 Q4 | - EUR | 0.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q1 | - EUR | 0.0% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 FY | -1.45 Million EUR | 61.3% |
| 2017 Q4 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 FY | -3.76 Million EUR | -65.66% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q3 | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2015 FY | -2.27 Million EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIVAX Société Anonyme | 1.00 EUR | -22099900.0% |
| Adocia SA | 272 Thousand EUR | 18.75% |
| Aelis Farma SA | 53 Thousand EUR | -316.981% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | 87.306% |
| genOway Société anonyme | 982.75 Thousand EUR | 77.512% |
| IntegraGen SA | 311.44 Thousand EUR | 29.041% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -34.247% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 119.934% |
| Plant Advanced Technologies SA | 1.22 Million EUR | 81.953% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 285.44% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -142.857% |
| Valbiotis SA | 1 Million EUR | 78.01% |
| TheraVet SA | 123.34 Thousand EUR | -79.177% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -22099900.0% |
| argenx SE | 281.12 Million EUR | 99.921% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | 82.46% |
| DBV Technologies S.A. | 1.00 USD | -22099900.0% |
| Galapagos NV | 73.97 Million EUR | 99.701% |
| Genfit S.A. | 4000.00 EUR | -5425.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -22099900.0% |
| Innate Pharma S.A. | 1.00 EUR | -22099900.0% |
| Inventiva S.A. | 417 Thousand EUR | 47.002% |
| MaaT Pharma SA | 190 Thousand EUR | -16.316% |
| MedinCell S.A. | -6.71 Million EUR | 103.292% |
| Nanobiotix S.A. | 200 Thousand EUR | -10.5% |
| Onward Medical N.V. | 936 Thousand EUR | 76.389% |
| Oryzon Genomics S.A. | 6029.00 EUR | -3565.616% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -72.656% |
| Pharming Group N.V. | 51.38 Million EUR | 99.57% |
| Poxel S.A. | 2.95 Million EUR | 92.524% |
| GenSight Biologics S.A. | 1.00 EUR | -22099900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 99.979% |
| Valneva SE | 44.46 Million EUR | 99.503% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -22099900.0% |